The price of Dendreon stocks dropped another 37% yesterday, down to 6.55$/share. it actually dropped all the way from 40$/share in 3 months. Why? because the company's individual service business model do not support a rapid growth. "Dendreon blamed the slow sales ramp on slow physician acceptance and uncertainty that they would be reimbursed for the expensive treatment." (By Bill Berkrot | Reuters – Wed, Nov 2, 2011). Manufacturing on a individual base is also a huge problem for them. ASTM will be facing the exact problems Dendreon is facing today. Dendreon's manufacturing process is actually easier than that of ASTM. They just need to take patient's blood, separate the dendritic cells, activate them, then put them back into the same patient. So it's clear, "only over-the-shelf " model can achieve much much more, which is the exact concept of PSTI's PLX-PAD cells.